Viewing Study NCT03746860



Ignite Creation Date: 2024-05-06 @ 12:23 PM
Last Modification Date: 2024-10-26 @ 12:58 PM
Study NCT ID: NCT03746860
Status: COMPLETED
Last Update Posted: 2021-05-17
First Post: 2018-11-12

Brief Title: NIS of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
Sponsor: ALK-Abelló AS
Organization: ALK-Abelló AS

Study Overview

Official Title: Non-interventional Study on the Safety and Use of Allergy Immunotherapy ACARIZAX 12 SQ-HDM in Real-life Clinical Practice in Adult Patients With House Dust Mite Allergy in France
Status: COMPLETED
Status Verified Date: 2021-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: CARIOCA
Brief Summary: Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX 12 SQ-HDM in real-life clinical practice in adults patients 18 years with house dust mite allergy over a period of 12 months
Detailed Description: Condition

persistent moderate to severe HDM allergic rhinitis despite use of symptom-relieving medication
HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis Patients asthma status should be carefully evaluated before the initiation of treatment

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
ID-RCB2017-A02668-45 OTHER Comité de Protection des Personnes SUD MEDITERRANNEE IV None